Aztreonam compared with gentamicin for treatment of serious urinary tract infections.
Publication/Presentation Date
6-16-1984
Abstract
52 patients with serious urinary tract infections were randomised to receive either aztreonam (35) or gentamicin (17). In the aztreonam group 23 patients had unqualified cures, 6 cures with relapse, and 6 cures with reinfection; the comparable numbers in the gentamicin group were 9, 1, and 4. There were no failures with aztreonam and 3 with gentamicin. The most important determinant of outcome was the presence or absence of urological abnormalities. 11 further patients, with renal failure or gentamicin-resistant isolates, treated with aztreonam were all cured. Toxic effects were limited to symptomless liver-function-test abnormalities with aztreonam , whereas deterioration in renal function occurred in 4 gentamicin-treated subjects. Urinary colonisation with group D streptococci occurred in 14 of 46 aztreonam -treated patients (1 required treatment) compared with only 1 of 17 gentamicin-treated patients. 97% of 309 consecutive gram-negative urinary isolates tested, including 50 Pseudomonas aeruginosa, were susceptible in vitro to aztreonam and 91% to gentamicin. Aztreonam may prove an effective and safe alternative to the aminoglycosides.
Volume
1
Issue
8390
First Page
1315
Last Page
1318
ISSN
0140-6736
Published In/Presented At
Sattler, F. R., Moyer, J. E., Schramm, M., Lombard, J. S., & Appelbaum, P. C. (1984). Aztreonam compared with gentamicin for treatment of serious urinary tract infections. Lancet (London, England), 1(8390), 1315–1318. https://doi.org/10.1016/s0140-6736(84)91817-8
Disciplines
Medicine and Health Sciences
PubMedID
6145024
Department(s)
Department of Medicine
Document Type
Article